Dr. Usha is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1725 W Harrison St
Suite 1010
Chicago, IL 60612Phone+1 312-942-5904Fax+1 312-942-3192- Is this information wrong?
Education & Training
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
California Pacific Medical CenterResidency, Internal Medicine, 1993 - 1997
St Petersburg State Pediatric Medicine AcademyClass of 1982
Certifications & Licensure
CA State Medical License 1995 - Present
IL State Medical License 1997 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer Start of enrollment: 2005 Jul 01
- Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2006 Nov 01
- Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer Start of enrollment: 2007 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Correction: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin‑treated breast cancer patients: a prospective exploratory study.Wei, C., Banach, K., Chu, J., Tung, L., Atallah, I., Cobleigh, M., Rao, R., Feinstein, S., Usha, L., Reiser, J., Okwuosa, T.> ;Cardio-Oncology. 2024 Feb 6
- 1 citationsSoluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study.Wei, C., Banach, K., Chu, J., Tung, L., Cobleigh, M., Rao, R., Feinstein, S., Usha, L., Reiser, J., Okwuosa, T., Atallah, I.> ;Cardio-Oncology. 2024 Jan 15
- Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors.Jordan Lieberenz, Mia Levy, Rosalinda Alvarado, Shirlene Paul, Melody Cobleigh, Lydia Usha, Lisa Stempel> ;Journal of the American College of Radiology. 2023 Jan 1
- Join now to see all
Journal Articles
- Can Chimerism Explain breast/ovarian Cancers in BRCA Non-Carriers from BRCA-Positive Families?Lydia Usha, Melody Cobleigh, PLoS One
Professional Memberships
- Member
Other Languages
- Russian
Hospital Affiliations
Rush University Medical CenterChicago, Illinois
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
